Home – Neuroscience – Temple University

Employ Your Mind

Our neuroscience degree program teaches students to explore neural and brain function at multiple levels in a rapidly growing field. Our students study the neural basis of addiction, developmental disorders, ADHD, depression, anxiety, age-related disorders and much more.

No matter what our students have planned for life after graduationfurther graduate study in neuroscience, medical school or entering the workforceour flexible curriculum allows time for classes outside of the major. As a student, youll get the well-rounded academic experience needed for your next stop.

Our students don't just learn from books. You'll get hands-on experience in research labs right here on campus and internship opportunities in the broader Philadelphia area.

Our competitive +1 program offers students the opportunity to earn both a bachelor's and master's degree in neuroscience in just five years.

Our interdisciplinary curriculum allows students to take coursework in multiple departments at Temple while engaging in the study of one of the most dynamic areas of science.

See original here:
Home - Neuroscience - Temple University

Department of Neuroscience – UT Southwestern, Dallas, TX

The Department of Neuroscience at UTSouthwestern Medical Center is dedicated to research into fundamental questions concerning neuronal and brain functions in health and diseases.

Neuroscience stands at the forefront of biology in the exploration of some of the most profound questions concerning living systems. The understanding of how nervous systems function and how they generate integrative behavior and cognition remain one of the most difficult challenges in science today.

The application of neural science to the study of behavior has made tremendous progress over the last five decades. Arguably, the success and remarkable growth of neuroscience can be attributed to its interdisciplinary nature and its ability to continue to incorporate new disciplines and technology.

Currently, neuroscience is entering yet another era with the revolution in genetics, genomics, biochemistry and structural biology. While biophysics using electrophysiological approaches has been a cornerstone of neuroscience, the disciplines of chemistry, structural biology and genetics have penetrated neuroscience only recently. These fundamental disciplines are critical for a mechanistic understanding of neural function. This interface is where UTSouthwestern excels and where fundamental new discoveries in neuroscience will be made in the coming century.

Neuroscience at UTSouthwestern is driven by a mechanistic understanding of the brain. That is what sets us apart from other neuroscience programs: our tradition in metabolism and genetics, pharmacology, chemistry, biochemistry, structural biology, and biophysics provides a unique and rich environment for understanding brain function at a mechanistic level.

The Department of Neuroscience was founded in 2007 and has grown substantially to more than 23 primary faculty members. Scientists within the Department of Neuroscience participate in a vibrant, interdisciplinary, interdepartmental, and highly collaborative research community.

The Department is a basic research facility, and does not perform clinical research. However, many projects pursued in the Department are likely to have a significant impact on understanding neurological and psychiatric diseases. It has become clear that significant progress in understanding disease is derived from insight into the normal functions of biological processes, and that basic research into the fundamental properties of a biological system and its perturbations in disease is the best approach to discover and develop new diagnostic and therapeutic methods.

The research in the Department on neurogenetics, genomics, neuronal development, circuit mechanisms, learning and memory, circadian biology, synaptic transmission, structural biology, and neurodegenerative processes will be particularly important in diseases such as autism spectrum disorder, Parkinson's disease, Alzheimer's disease, depression, and schizophrenia in which these processes are affected.

See the article here:
Department of Neuroscience - UT Southwestern, Dallas, TX

What is Neuroscience? – allpsychologycareers.com

Rapid advances in technology combined with knowledge about how the brain and nervous system work have ushered in progress once considered purely science fiction, but today falling under a growing area of scientific study called neuroscience.

Take, for example, the case of implanting a sensor into a paralyzed individuals brain. The sensor detects thoughts that the individual has about moving an arm. These thoughts are then sent to a plug on the individuals scalp, which sends signals to a computer that translates the signals into motor movements.

Or consider the practice of placing electrodes under a persons scalp, electrodes connected to a battery-operated generator implanted under the skin near the individuals collarbone. The result? An intervention for a brain-related disorder called essential tremor.

Both of these cutting-edge medical interventions wouldnt have been possible without the field of Neuroscience, an area of specialty that wasnt formalized into its own field until 1971. Since then, the amount of investigation and research completed by those working in the field has grown faster than most other scientific areas of thought and empirical study.

And those individuals with devastating brain and spinal cord injuries, brain diseases and disorders, are the main beneficiaries of these once unimaginable scientific advancements.

The Society for Neuroscience (SfN) defines neuroscience as the study of the nervous system, including the brain, spinal cord, and networks of sensory nerve cells called neurons. It is an interdisciplinary field, meaning that it integrates several disciplines, including psychology, biology, chemistry, and physics.

In studying the nervous system, the field adds to a body of knowledge about human thought, emotion, and behavior the main area of expertise for those working in psychology, especially the field of Neuropsychology.

Both neuropsychologists and neuroscientists focus their research on the understanding of brain disorders, injuries, and deficits. For this reason, these scientists must have a solid understanding of how psychological processes relate to the brains structures and systems, or on the interrelated and inseparable connections between cognition and brain physiology.

To help those with brain disorders, neuroscientists first must understand normal brain functioning. Therefore, many neuroscientific investigations into abnormal brain functioning complement the science of normal brain functioning.

Neuroscientists study a wide range of topics related to the brain and nervous system. Most specialize, however, on a particular disability or problem associated with one brain region or area. The implanting of brain sensors is one example of specialized neuroscientific research.

In an August 2010 interview with The New York Times, John Donohue detailed how his research into combining brain signals with computers resulted in BrainGate, the invention responsible for returning some voluntary movements to paralyzed individuals. He has focused on using BrainGate to help those who have had strokes, incurred spinal cord injuries, or suffer with amyotrophic lateral sclerosis (ALS).

Donoghue, a professor of engineering and neuroscience at Brown University, told reporter Claudia Dreifus, in the article Connecting Brains to the Outside World, that when he entered graduate school in 1976, his desire was to learn how the brain works. But, he realized that that question was too broad, and he needed to break it down into a more easily studied sub-topic, which became how does the cerebral cortex allow thoughts to become action?

In the 1980s, he and colleagues from his laboratory worked on technologies that permitted them to distinguish where brain activity occurred when the body moved, such as when arms or legs moved. These technologies led to the invention of the brain sensor.

In 2004, Donoghue and other researchers implanted the sensor into an individual that had a spinal cord injury that left him paralyzed. When they turned on BrainGate the sensor attached to a scalp plug thats attached to a computer they could see activity in his brain light up when he thought about moving his left or right hand. In other words, even though his body couldnt produce the movement, his brain still processed the command.

In the NYT article, Donohue related how up until that point, many assumed that brain function was reduced or nonexistent after a debilitating spinal cord injury. But this new technology pointed out that it was the connection between the brain and the desired movement that was injured, not the brain itself. In other words, theres a break or disconnect between the brain the other parts of the nervous system.

This has profound implications not for only BrainGate, but for anyone thinking about nervous system injuries, Donohue told the NYT.

Ultimately, Donoghue said, at the goal of BrainGate is to return lives impacted by neurological injuries back to a state of normalcy, or as close as possible to the productive lives they had before the injuries or illnesses.

Neuroscientists at the Mayo Clinic also want individuals suffering with brain and neurological disorders to regain normal functioning and their livelihoods. In its quarterly publication, Sharing Mayo Clinic, Mayo describes how its research into deep brain stimulation (DBS) led to some of the first applications of this technology in the United States.

In one particular case, world-renowned violinist Roger Frisch, associate concertmaster of the Minnesota Orchestra, thought his music career would be over after being diagnosed with a condition known as essential tremor.

A progressive neurological disorder, essential tremor results in tremors during certain movements, such as eating or writing. Tremors can also occur in the head, neck, jaw, and voice.

In Frischs case, the tremors occurred in his arms while performing. Kendall Lee, M.D., Ph.D., and specialist in DBS at Mayo Clinic, believed that locating the tremors source, or area of Frischs brain where the tremors materialized, could help alleviate them.

In order to accomplish this localization, Mayos surgical team had Frisch perform in the surgical suite where a device engineered by Mayos researchers measured the exact movement of Frischs hand, tracing and mapping the movement to the area of the activated brain.

The newsletter called the device an accelerometer, a small semiconductor device that measures movement in three dimensions. It was attached to a violin bow and connected to an amplifier and radio system.

The device transmitted data to a computer monitor where the research team saw the genesis and progress of the tremor as the bow moved across the strings. Electrodes were placed on Frischs skull where the researchers located the misfiring brain signals, and the tremors stopped.

Frisch then went into surgery so that the wires could be placed under the scalp and connected to a battery-operated pulse generator that sends constant electrical pulses to the brain. The generator is implanted under the skin by the collarbone.

If you are interested in the fields of Neuropsychology and Neuroscience, in research and medical facilities designed to treat individuals suffering from brain injuries and dysfunctions, contact schools offering degrees in psychology. One career path for neuroscience professionals is to major in neuropsychology and take additional coursework in biology, physiology, anatomy, chemistry, and other sciences. A Ph.D. is required to work in most areas of neuroscience.

Diagnosing traumatic brain injury (TBI) remains a tedious and often difficult process for many healthcare professionals, especially in cases of mild or moderate TBI. As a result, some individuals dont receive treatment or intervention for possible neurological deficits.

Banyan Biomarkers, a Florida-based privately held company wants to solve that problem.

Founded by two neuroscientists, Banyans researchers are trying to identify biomarkers in blood tests that accurately predict head injury. Research by Banyans scientists and published in the journal Critical Care Medicine, stated that a 66-patient study of individuals with severe brain injury had elevated levels of UCH-LI 16 times the level of those without a head injury.

Banyans scientists also stated in another article for the European Journal of Neuroscience that laboratory studies with rats showed blood tests with increased levels of UCH-LI for those with brain injury and stroke.

Battlefield explosions and sports injuries often leave individuals dazed but seemingly fine, performing some neurological tests adequately, but actually needing medical treatment, rest and recovery.

According to the International Brain Injury Association, the Glasgow Coma Scale (GCS) is currently used to divide individuals into mild, moderate, and severe injury. This is a symptom-based neurological test, checking vital signs, heart rate, blood pressure, and the patients thinking in terms of memory and consciousness.

A blood test showing a definitive marker for brain injury would significantly increase an accurate diagnosis for those with mild and moderate head injuries.

Of the mild TBI patients 40-50% suffer persistent neurological problems from one to three months following injury, and 25% after one year, according to the International Brain Injury Association website.

Even severe cases of brain injury can be hard to recognize. In 2009, actress Natasha Richardson died from a skiing accident that injured her head. Assuring her family that she was fine, she did not receive medical treatment as quickly as her injury required.

See the original post here:
What is Neuroscience? - allpsychologycareers.com

Neuroscience – College of Arts and Sciences – Santa Clara …

A Bachelor of Science degree in neuroscience at SCU will provide students with the scientific foundation needed to understand the nervous system at many levels, from the molecular level to patient symptomatology. Students will examine the biological and psychological underpinnings of the nervous system, they will come to appreciate the role of the environment in contributing to disease, disorders and development, and they will be challenged to consider ethical issues of brain-behavior relationships in criminology, health care, diagnosis and treatment.

Read the original:
Neuroscience - College of Arts and Sciences - Santa Clara ...

Plant genetics – Wikipedia

Plant genetics is the study of genes, genetic variation, and heredity specifically in Plants.[1][2] It is generally considered a field of biology and botany, but intersects frequently with many other life sciences and is strongly linked with the study of information systems. Plant genetics is similar in many ways to animal genetics but differs in a few key areas.

The discoverer of genetics is Gregor Mendel, a late 19th-century scientist and Augustinian friar. Mendel studied "trait inheritance", patterns in the way traits are handed down from parents to offspring. He observed that organisms (pea plants) inherit traits by way of discrete "units of inheritance". This term, still used today, is a somewhat ambiguous definition of what is referred to as a gene. Much of Mendel's work with plants still forms the basis for modern plant genetics.

Plants, like all known organisms, use DNA to pass on their traits. Animal genetics often focuses on parentage and lineage, but this can sometimes be difficult in plant genetics due to the fact that plants can, unlike most animals, can self-fertilize. Speciation can be easier in many plants due to unique genetic abilities, such as being well adapted to polyploidy. Plants are unique in that they are able to make their own food via photosynthesis, a process which is achieved by use of a structure mostly exclusive to plants: chloroplasts. Chloroplasts, like the superficially similar mitochondria, possess their own DNA. Chloroplasts thus provide an additional reservoir for genes and genetic diversity, and an extra layer of genetic complexity not found in animals.

The study of plant genetics has major economic impacts: many staple crops are genetically modified to increase yields, confer pest and disease resistance, provide resistance to herbicides, or to increase their nutritional value.

The field of plant genetics began with the work of Gregor Mendel, who is often called the "father of genetics". He was an Augustinian priest and scientist born on 20 July 1822 in Austria-Hungary. He worked at the Abbey of St. Thomas in Brno , where his organism of choice for studying inheritance and traits was the pea plant. Mendel's work tracked many phenotypic traits of pea plants, such as their height, flower color, and seed characteristics. Mendel showed that the inheritance of these traits follows particular laws, which were later named after him. His seminal work on genetics was published in 1866, but went almost entirely unnoticed until 1900. Mendel died in 1884. The significance of Mendel's work was not recognized until the turn of the 20th century. Its rediscovery prompted the foundation of modern genetics.

Deoxyribonucleic acid (DNA) is a nucleic acid that contains the genetic instructions used in the development and functioning of all known living organisms and some viruses. The main role of DNA molecules is the long-term storage of information. DNA is often compared to a set of blueprints or a recipe, or a code, since it contains the instructions needed to construct other components of cells, such as proteins and RNA molecules. The DNA segments that carry this genetic information are called genes, but other DNA sequences have structural purposes, or are involved in regulating the use of this genetic information. Geneticists, including plant geneticists, use this sequencing of DNA to their advantage as they splice and delete certain genes and regions of the DNA molecule to produce a different or desired genotype and thus, also producing a different phenotype.

Plants, like all other known living organisms, pass on their traits using DNA. Plants however are unique from other living organisms in the fact that they have Chloroplasts. Like mitochondria, chloroplasts have their own DNA. Like animals, plants experience somatic mutations regularly, but these mutations can contribute to the germ line with ease, since flowers develop at the ends of branches composed of somatic cells. People have known of this for centuries, and mutant branches are called "sports". If the fruit on the sport is economically desirable, a new cultivar may be obtained.

Some plant species are capable of self-fertilization, and some are nearly exclusively self-fertilizers. This means that a plant can be both mother and father to its offspring, a rare occurrence in animals. Scientists and hobbyists attempting to make crosses between different plants must take special measures to prevent the plants from self-fertilizing. In plant breeding, people create hybrids between plant species for economic and aesthetic reasons. For example, the yield of Corn has increased nearly five-fold in the past century due in part to the discovery and proliferation of hybrid corn varieties.[3] Plant genetics can be used to predict which combination of plants may produce a plant with Hybrid vigor, or conversely many discoveries in Plant genetics have come from studying the effects of hybridization.

Plants are generally more capable of surviving, and indeed flourishing, as polyploids. Polyploid organisms have more than two sets of homologous chromosomes. For example, humans have two sets of homologous chromosomes, meaning that a typical human will have 2 copies each of 23 different chromosomes, for a total of 46. Wheat on the other hand, while having only 7 distinct chromosomes, is considered a hexaploid and has 6 copies of each chromosome, for a total of 42.[4] In animals, inheritable germline polyploidy is less common, and spontaneous chromosome increases may not even survive past fertilization. In plants however this is no such problem, polyploid individuals are created frequently by a variety of processes, however once created usually cannot cross back to the parental type. Polyploid individuals, if capable of self-fertilizing, can give rise to a new genetically distinct lineage, which can be the start of a new species. This is often called "instant speciation". Polyploids generally have larger fruit, an economically desirable trait, and many human food crops, including wheat, maize, potatoes, peanuts,[5] strawberries and tobacco, are either accidentally or deliberately created polyploids.

Arabidopsis thaliana, also known as thale cress, has been the model organism for the study of plant genetics. As Drosphila, a species of fruit fly, was to the understanding of early genetics, so has been arabidopsis to the understanding of plant genetics.

Genetically modified (GM) foods are produced from organisms that have had changes introduced into their DNA using the methods of genetic engineering. Genetic engineering techniques allow for the introduction of new traits as well as greater control over traits than previous methods such as selective breeding and mutation breeding.[6]

Genetically modifying plants is an important economic activity: in 2017, 89% of corn, 94% of soybeans, and 91% of cotton produced in the US were from genetically modified strains[7]. Since the introduction of GM crops, yields have increased by 22%, and profits have increased to farmers, especially in the developing world, by 68%. An important side effect of GM crops has been decreased land requirements, [8]

Commercial sale of genetically modified foods began in 1994, when Calgene first marketed its unsuccessful Flavr Savr delayed-ripening tomato.[9][10] Most food modifications have primarily focused on cash crops in high demand by farmers such as soybean, corn, canola, and cotton. Genetically modified crops have been engineered for resistance to pathogens and herbicides and for better nutrient profiles.[11] Other such crops include the economically important GM papaya which are resistant to the highly destructive Papaya ringspot virus, and the nutritionally improved golden rice (it is however still in development).[12]

There is a scientific consensus[13][14][15][16] that currently available food derived from GM crops poses no greater risk to human health than conventional food,[17][18][19][20][21] but that each GM food needs to be tested on a case-by-case basis before introduction.[22][23] Nonetheless, members of the public are much less likely than scientists to perceive GM foods as safe.[24][25][26][27] The legal and regulatory status of GM foods varies by country, with some nations banning or restricting them, and others permitting them with widely differing degrees of regulation.[28][29][30][31] There are still ongoing public concerns related to food safety, regulation, labeling, environmental impact, research methods, and the fact that some GM seeds are subject to intellectual property rights owned by corporations.[32]

Genetic modification has been the cause for much research into modern plant genetics, and has also lead to the sequencing of many plant genomes. Today there are two predominant procedures of transforming genes in organisms: the "Gene gun" method and the Agrobacterium method.

The gene gun method is also referred to as "biolistics" (ballistics using biological components). This technique is used for in vivo (within a living organism) transformation and has been especially useful in monocot species like corn and rice.This approach literally shoots genes into plant cells and plant cell chloroplasts. DNA is coated onto small particles of gold or tungsten approximately two micrometres in diameter. The particles are placed in a vacuum chamber and the plant tissue to be engineered is placed below the chamber. The particles are propelled at high velocity using a short pulse of high pressure helium gas, and hit a fine mesh baffle placed above the tissue while the DNA coating continues into any target cell or tissue.

Transformation via Agrobacterium has been successfully practiced in dicots, i.e. broadleaf plants, such as soybeans and tomatoes, for many years. Recently it has been adapted and is now effective in monocots like grasses, including corn and rice. In general, the Agrobacterium method is considered preferable to the gene gun, because of a greater frequency of single-site insertions of the foreign DNA, which allows for easier monitoring. In this method, the tumor inducing (Ti) region is removed from the T-DNA (transfer DNA) and replaced with the desired gene and a marker, which is then inserted into the organism. This may involve direct inoculation of the tissue with a culture of transformed Agrobacterium, or inoculation following treatment with micro-projectile bombardment, which wounds the tissue.[33] Wounding of the target tissue causes the release of phenolic compounds by the plant, which induces invasion of the tissue by Agrobacterium. Because of this, microprojectile bombardment often increases the efficiency of infection with Agrobacterium. The marker is used to find the organism which has successfully taken up the desired gene. Tissues of the organism are then transferred to a medium containing an antibiotic or herbicide, depending on which marker was used. The Agrobacterium present is also killed by the antibiotic. Only tissues expressing the marker will survive and possess the gene of interest. Thus, subsequent steps in the process will only use these surviving plants. In order to obtain whole plants from these tissues, they are grown under controlled environmental conditions in tissue culture. This is a process of a series of media, each containing nutrients and hormones. Once the plants are grown and produce seed, the process of evaluating the progeny begins. This process entails selection of the seeds with the desired traits and then retesting and growing to make sure that the entire process has been completed successfully with the desired results.

Domingo, Jos L.; Bordonaba, Jordi Gin (2011). "A literature review on the safety assessment of genetically modified plants" (PDF). Environment International. 37: 734742. doi:10.1016/j.envint.2011.01.003. PMID21296423.

Krimsky, Sheldon (2015). "An Illusory Consensus behind GMO Health Assessment" (PDF). Science, Technology, & Human Values. 40: 132. doi:10.1177/0162243915598381.

And contrast:

Panchin, Alexander Y.; Tuzhikov, Alexander I. (January 14, 2016). "Published GMO studies find no evidence of harm when corrected for multiple comparisons". Critical Reviews in Biotechnology: 15. doi:10.3109/07388551.2015.1130684. PMID26767435.

and

Yang, Y.T.; Chen, B. (2016). "Governing GMOs in the USA: science, law and public health". Journal of the Science of Food and Agriculture. 96: 18511855. doi:10.1002/jsfa.7523. PMID26536836.

Pinholster, Ginger (October 25, 2012). "AAAS Board of Directors: Legally Mandating GM Food Labels Could "Mislead and Falsely Alarm Consumers"". American Association for the Advancement of Science. Retrieved February 8, 2016.

See the article here:
Plant genetics - Wikipedia

Analysts Set $4.35 Price Target for Fulgent Genetics Inc …

Fulgent Genetics Inc (NASDAQ:FLGT) has been assigned a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.

Brokers have set a 1 year consensus price objective of $4.35 for the company and are anticipating that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also given Fulgent Genetics an industry rank of 70 out of 255 based on the ratings given to related companies.

Several equities analysts have recently weighed in on FLGT shares. Credit Suisse Group decreased their price target on shares of Fulgent Genetics from $6.50 to $6.00 and set an outperform rating on the stock in a research note on Thursday, March 1st. Piper Jaffray Companies downgraded shares of Fulgent Genetics from an overweight rating to a neutral rating in a research note on Thursday, March 1st. Finally, ValuEngine raised shares of Fulgent Genetics from a sell rating to a hold rating in a research note on Wednesday, May 2nd.

Shares of Fulgent Genetics traded down $0.27, hitting $4.19, during midday trading on Friday, MarketBeat.com reports. The companys stock had a trading volume of 11,472 shares, compared to its average volume of 12,262. The company has a market cap of $79.79 million, a P/E ratio of -38.09 and a beta of 0.28. Fulgent Genetics has a 12-month low of $2.72 and a 12-month high of $7.04.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings results on Monday, May 7th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.04) by ($0.02). The business had revenue of $4.65 million during the quarter. Fulgent Genetics had a negative return on equity of 7.62% and a negative net margin of 26.57%. analysts expect that Fulgent Genetics will post -0.29 earnings per share for the current year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.

Get a free copy of the Zacks research report on Fulgent Genetics (FLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Analysts Set $4.35 Price Target for Fulgent Genetics Inc ...

Myriad Genetics (MYGN) versus Quotient (QTNT) Head-To-Head …

Myriad Genetics (NASDAQ: MYGN) and Quotient (NASDAQ:QTNT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Risk & Volatility

Myriad Genetics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Quotient has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

This table compares Myriad Genetics and Quotients net margins, return on equity and return on assets.

Insider & Institutional Ownership

61.5% of Quotient shares are owned by institutional investors. 6.7% of Myriad Genetics shares are owned by company insiders. Comparatively, 29.0% of Quotient shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Myriad Genetics and Quotient, as reported by MarketBeat.

Myriad Genetics currently has a consensus price target of $30.91, suggesting a potential downside of 20.48%. Quotient has a consensus price target of $11.50, suggesting a potential upside of 30.68%. Given Quotients stronger consensus rating and higher probable upside, analysts plainly believe Quotient is more favorable than Myriad Genetics.

Earnings and Valuation

This table compares Myriad Genetics and Quotients gross revenue, earnings per share and valuation.

Myriad Genetics has higher revenue and earnings than Quotient. Quotient is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Summary

Myriad Genetics beats Quotient on 8 of the 13 factors compared between the two stocks.

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It also develops, manufactures, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to donor collection agencies and testing laboratories, hospitals, independent patient testing laboratories, reference laboratories, blood banking operations, and other diagnostic companies, as well as to original equipment manufacturers. Quotient Limited was founded in 2007 and is based in Penicuik, the United Kingdom.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Continued here:
Myriad Genetics (MYGN) versus Quotient (QTNT) Head-To-Head ...

Immunology | Janssen

Jennifer Jacobs

Stuyvesant Park

Jennifer is a practicing New York City artist who was diagnosed with Type 1 diabetes at the age of twelve. She refers to her art as a picture essay about this exasperating, mysterious, unpredictable, motivating, fascinating, relentless nuisance.

The rest is here:
Immunology | Janssen

Genentech: Immunology

We're constantly growing our expertise in Immunology so that we can continue to discover and develop innovative medicines for patients living with debilitating diseases, such as systemic lupus erythematosus, rheumatoid arthritis, asthma, inflammatory bowel disease, and idiopathic pulmonary fibrosis.

At Genentech our research and discovery efforts into aspects of innate and adaptive immunity are applied to the understanding and treatment of autoimmune, inflammatory and fibrotic disorders. Studying how interactions between the immune system, stromal and epithelial cells, and the environment can become dysregulated in specialized tissues underlies our strategy to develop novel therapies for the treatment of autoimmune, inflammatory, and fibrotic diseases. We rely on human patient samples and biomarker data from observational and interventional clinical trials to define the pathogenic mechanisms and mechanistically distinct patient subsets underlying unmet medical needs in complex chronic diseases.

Science Signal, April 2017

The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation

Nature, December 2015

Therapeutic antibodies reveal Notch control of transdifferentation in the adult lung

Nature, October 2015

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling

Science Translational Medicine, August 2015

TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma

Nature, October 2014

Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes

Nature, February 2014

A Crohns disease variant in Atg16l1 enhances its degradation by caspase 3

Nature, February 2014

Genetics of rheumatoid arthritis contributes to biology and drug discovery

See the original post here:
Genentech: Immunology